X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Under the agreement, BWXT Medical, will provide Fusion with a preferential supply of radium-225 and access to high-specific activity generator technology, enabling Fusion for advancing its pipeline of targeted alpha therapies.
Lead Product(s): Actinium-225
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Fusion Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration November 16, 2023
Details:
The proceeds will advance IND enabling activities and clinical development of RYZ801, a novel proprietary peptide which targets GPC3 for delivery of Ac225, and RYZ811 in HCC through Phase 1b safety data and the development of RYZ101 for GEP-NETs and extensive-stage SCLC.
Lead Product(s): RYZ801,Actinium-225
Therapeutic Area: Oncology Product Name: RYZ801
Highest Development Status: IND EnablingProduct Type: Peptide
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering August 25, 2023
Details:
The collaboration aims to evaluate radiopharmaceutical versions of MNPR-101 RIT in several aggressive cancers. MNPR-101 is a novel, first-in-class humanized monoclonal antibody to the urokinase Plasminogen Activator Receptor (uPAR).
Lead Product(s): MNPR-101,Actinium-225
Therapeutic Area: Oncology Product Name: MNPR-101 RIT
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Cancer Science Institute of Singapore
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 11, 2023
Details:
RYZ101 is an investigational targeted radiopharmaceutical therapy, designed to deliver a highly potent radioisotope, Actinium-225 (Ac225), to tumors expressing SSTR2.
Lead Product(s): Actinium-225
Therapeutic Area: Oncology Product Name: RYZ101
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2023
Details:
Actinium-225 is an alpha emitting radioactive particle that has high energy density acting at distances of just a few cell widths. At these short distances, radiation can be restricted to the cancer cells of interest with minimal risk to nearby normal healthy tissue.
Lead Product(s): Actinium-225
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Yonghe Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 27, 2022
Details:
PNT2001 displays enhanced internalization, biodistribution, and pre-clinical efficacy in multiple tumor models, making it a prime candidate for the delivery of actinium-225.
Lead Product(s): Actinium-225
Therapeutic Area: Oncology Product Name: PNT2001
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2022
Details:
Proceeds from the financing will be used by Ablaze to establish a leading pipeline of advanced TRT products having Actinium-225 for the treatment of solid tumors, build up infrastructure for radiopharmaceuticals and secure further strategic collaborations.
Lead Product(s): Actinium-225
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Vivo Capital
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing November 29, 2021
Details:
Actinium evaluated the anti-HER2 antibody trastuzumab (Herceptin®) conjugated with either Actinium-225 (Ac-225) or Lutetium-177 (Lu-177) radioisotope payloads to explore potential synergies in combination with CD47 blocking antibodies.
Lead Product(s): Trastuzumab,Actinium-225,CD47 antibody
Therapeutic Area: Oncology Product Name: Herceptin
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 12, 2021
Details:
PDS Biotechnology licenses National Cancer Institute for intellectual property related to tumor-associated active T-cell receptor gamma. The administration of PDS0102, Versamune-TARP tumor antigen combination, led to induction of large numbers of tumor targeted killer T-cells.
Lead Product(s): PNT2001,Actinium-225
Therapeutic Area: Oncology Product Name: PNT2001
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Ionetix
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 09, 2021
Details:
BWXT Medical plans to utilize its deep relationships with strategic partner Bayer in irradiation services and development of Actinium-225 (Ac-225). Ac-225 is a highly powerful radioisotope used in targeted alpha therapies (TATs).
Lead Product(s): Actinium-225
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: BWXT Medical Ltd.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 16, 2021
Details:
Under the terms of the agreement, NorthStar will provide POINT with its electron accelerator-produced Ac-225 and POINT will use NorthStar’s Ac-225 in studies of PNT2001, a next-generation Prostate-Specific Membrane Antigen for non-metastatic castrate-sensitive prostate cancer.
Lead Product(s): PNT2001,Actinium-225
Therapeutic Area: Oncology Product Name: PNT2001
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Point Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 08, 2021
Details:
IPN-1087 is a small molecule targeting neurotensin receptor 1 (NTSR1), a protein expressed on multiple solid tumor types. Fusion intends to use IPN-1087 to create an alpha-emitting radiopharmaceutical, FPI-2059, targeting solid tumors expressing NTSR1.
Lead Product(s): IPN-1087,Actinium-225
Therapeutic Area: Oncology Product Name: FPI-2059
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Fusion Pharma
Deal Size: $579.4 million Upfront Cash: Undisclosed
Deal Type: Acquisition April 01, 2021
Details:
Preclinical feasibility data supporting an Actinium-225-based CD45-targeted Next-Generation conditioning agent has been accepted for poster presentation at the American Association of Cancer Research (AACR 2021) annual meeting being held virtually April 10th – 15th, 2021.
Lead Product(s): Actinium-225
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2021
Details:
RayzeBio has secured relationships with suppliers of Actinium-225. Actinium-225, an alpha-emitting isotope, is the primary nuclear payload for RayzeBio given its potent cell killing and focused energy release to a few cell diameters without surrounding normal tissues.
Lead Product(s): Actinium-225,Macrocyclic peptide mimetics
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: venBio Partners
Deal Size: $45.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing October 14, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
